Peter Hecht has served as Ironwood’s CEO and a director since co‐founding the company in 1998. He started Ironwood because he was attracted to “the idea of working with a team of people who challenge, inspire and humble me,” and building an enduring organization dedicated to creating important medicines. Under his leadership, Ironwood has grown from nine Ph.D. scientists to a commercial biotechnology company. Prior to founding Ironwood, Peter was a research fellow at Whitehead Institute for Biomedical Research, an affiliate of Massachusetts Institute of Technology (MIT). He earned his Ph.D. in molecular biology from the University of California at Berkeley as well as a B.S. in mathematics and an M.S. in biology from Stanford University.
Brian Cali co-founded Ironwood in 1998, with the goal of helping to translate scientific insights into medicines that make a difference for patients. As Senior Vice President, R&D Strategy and External Innovation, Brian is focused on ensuring tight integration between Ironwood’s R&D strategy and its overall corporate and commercial strategies, and guiding the search for product candidates, technologies and scientific innovations that can advance the company’s mission. He previously served as Senior Vice President of Preclinical Research and Development, during which time his team identified and advanced a number of new pipeline candidates targeting gastrointestinal disorders and vascular and fibrotic diseases. Prior to this, Brian created and led the program management function at Ironwood. Before Ironwood, Brian was a Chiron Fellow of the Life Sciences Research Foundation at Whitehead Institute for Biomedical Research. He holds a Ph.D. in cellular and molecular biology from the University of Wisconsin–Madison and earned a B.S. in microbiology from Cornell University.
Gina Consylman is a 25-year veteran in the field of corporate finance, accounting and tax. She joined Ironwood in 2014 and currently oversees the company's finance, planning, accounting, tax, treasury and insurance functions. Prior to joining Ironwood, Gina was vice president, corporate controller and principal accounting officer at Analogic Corporation, a publicly-held healthcare and security technology solutions company, where she oversaw the company's global accounting and treasury teams. Prior to her work at Analogic, Gina served as senior director, corporate accounting at Biogen Inc., where she led the accounting teams for the corporate and U.S. commercial business units, and as corporate controller at Varian Semiconductor Equipment Associates, Inc. (acquired by Applied Materials, Inc.). Gina, a Certified Public Accountant, began her career in public accounting at Ernst & Young LLP. She holds a B.S. in accounting from Johnson & Wales University and a M.S. in taxation from Bentley University.
Mark Currie has led Ironwood’s R&D efforts since joining Ironwood in 2002. He led the discovery of the natural hormones (guanylin and uroguanylin) that activate guanylate cyclase‐C (GC‐C), a target thought to be useful in the treatment of a number of gastrointestinal diseases, and he brought a unique understanding of GC‐C pharmacology to Ironwood. This expertise in GC‐C and related cyclic guanosine monophosphate pathways supported our team’s discovery and development of our first medicine. Prior to joining Ironwood, Mark directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, Inc. He also initiated, built and led discovery pharmacology and served as director of arthritis and inflammation at Monsanto Company, leading an effort that resulted in marketed Cox‐2 inhibitors for the treatment of pain in humans and animals. Mark earned a Ph.D. in cell biology from the Bowman‐Gray School of Medicine of Wake Forest University and a B.S. in biology from the University of South Alabama.
Halley Gilbert joined Ironwood in 2008 as the founding member of our legal department, providing leadership and oversight and establishing our company’s compliance function as Ironwood grew from a privately-held, research-based organization to a publicly-traded, fully-integrated commercial biotechnology company. Halley brings significant strategic leadership and two decades of experience navigating biopharmaceutical companies through transformational change, as well as expertise in corporate transactions, corporate governance, employment law and legal and operational issues relevant to launching new medicines into specialty and primary care markets. Prior to joining Ironwood, Halley was Vice President, Deputy General Counsel at Cubist Pharmaceuticals, Inc. from 2002 to 2008, where she supported the launch of Cubist’s first acute care antibiotic, and she served as Corporate Counsel at Genzyme Corp. from 1999 to 2001. Halley began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. She serves on the board of directors of Achaogen, Inc., a clinical-stage biopharmaceutical company focused on the development of novel antibacterials, and holds a J.D. from Northwestern University School of Law and a B.A. from Tufts University.
Bill Huyett joined Ironwood as chief operating officer in 2017, following a distinguished 30-year career at McKinsey and Company, Inc. He brings to Ironwood extensive experience in corporate strategy, capital allocation, finance, product development/commercialization and corporate leadership primarily in the life sciences industry, among other business sectors, and has a deep understanding of discovery, drug development and commercial functions. Most recently, Bill was a senior partner emeritus at McKinsey. He was a leader in the firm’s pharmaceutical and medical products and its strategy and corporate finance practices, and served on McKinsey’s Shareholder’s Council (its board of directors), serving as chair of its Finance Committee. Bill serves on the board of directors of the London Stock Exchange-listed Georgia Healthcare Group PLC. He also serves on several not-for-profit boards, including The Rockefeller University, the Marine Biological Laboratory, the University of Virginia Darden School of Business and the YMCA of Greater Boston. He earned his B.S. in electronics engineering and his M.B.A. from the University of Virginia.
Senior Vice President, Marketing & Sales
Tom McCourt joined Ironwood as chief commercial officer and senior vice president of marketing and sales in 2009. He was drawn to Ironwood by the quality and values of the people and by the potential he saw in our first product. Since coming on board, Tom has designed and implemented Ironwood’s commercial strategy, leading the hiring of a sales force and bringing our first medicine to patients. Prior to joining Ironwood, Tom led the U.S. brand team for denosumab at Amgen Inc. Before that, he held a number of senior commercial roles with Novartis AG, where he directed the launch and growth of Zelnorm® (tegaserod maleate) for the treatment of patients with IBS‐C and chronic constipation and held a number of senior commercial roles, including vice president of strategic marketing and operations. Tom was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and serving as brand manager for Prilosec® (omeprazole). Tom serves on the board of directors of Acceleron Pharma Inc. and has a degree in pharmacy from the University of Wisconsin.
Jonathan Rosin joined Ironwood as head of human resources in early 2012. He’s committed to building and developing Ironwood’s team as well as supporting a collaborative environment. Jonathan brings to Ironwood more than 20 years of experience in talent management, organizational development and leadership. Most recently, he was vice president of talent management at Fidelity Investments, and before that, director of leadership and organizational development at Genzyme Corp. Jonathan previously spent eight years with the Forum Corp., a talent and customer experience consulting firm supporting multiple industries. Born in South Africa, Jonathan graduated as a clinical psychologist from the University of Cape Town.
Chris Wright joined Ironwood in 2017, bringing nearly two decades of experience in the biopharmaceutical industry and academia. Prior to joining Ironwood, Chris served as senior vice president and chief medical officer for Axcella Health, Inc. Before that, he worked at Vertex Pharmaceuticals, Inc. for seven years, including serving as senior vice president and head of global medicine development and affairs, where he led global development functions across all therapeutic areas of clinical development, medical affairs, clinical operations, medical writing, biometrics, regulatory affairs and patient safety. In this role, Chris directly oversaw the successful submission of medications for approval to the FDA, EMA and other drug approval entities. Also at Vertex, Chris served as vice president of clinical development, where he oversaw clinical programs in the areas of hepatitis C, cystic fibrosis, rheumatoid arthritis, influenza, epilepsy and pain. Chris is a practicing neurologist at Brigham and Women's Hospital, and was an associate professor of neurology at Harvard Medical School and a Harvard-MIT Clinical Investigator Training Program graduate and advisor. He earned a B.S. in biochemical sciences from Harvard University, an M.D. and MMSc. from Harvard Medical School and a Ph.D. from Vrije University in Amsterdam, the Netherlands.